STOCK TITAN

Pacira BioSciences completes $36.50-a-share merger

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Pacira BioSciences, Inc. (PCRX) completed its merger with Viatris on November 17, 2026, becoming Viatris’ wholly owned subsidiary. Each eligible outstanding Pacira share converted into the right to receive $36.50 in cash, subject to applicable withholding taxes and without interest. Shares held by Pacira, its subsidiaries, Viatris or its subsidiaries, and shares with perfected appraisal rights were excluded.

The transaction required approximately $1.69 billion to pay for shares in the offer and merger and repay certain Pacira debt; the amount excludes deal fees and expenses and Pacira cash and cash equivalents assumed by Viatris. Pacira repaid $96,392.50 outstanding under its credit agreement and terminated the agreement and commitments; related liens will be released. Its $287.5 million of 2.125% convertible notes due 2029 now convert only into cash, not Pacira shares.

For notes validly surrendered from November 17, 2026 through 5:00 p.m. New York City time on January 8, 2027, the cash conversion amount is $1,103.8914 per $1,000 principal, including the make-whole increase. After that period, when notes are otherwise convertible, the amount is $922.5448 per $1,000 principal. Cash is payable on the tenth Business Day after conversion.

Filing Explained

Capped-call counterparties agreed to pay Pacira cash; Nasdaq trading suspension and delisting steps were requested, while reporting termination remains only planned.

Following the completed merger, Pacira says it relied on Section 14.05 of the notes indenture and will not offer to repurchase the notes in connection with the transaction.

Pacira also entered into unwind agreements for each capped-call confirmation; the counterparties agreed to pay Pacira cash on or about November 17, 2026.

Pacira notified Nasdaq of the merger closing and requested a trading halt before market open and a Form 25 delisting filing; it said it intends to file Form 15 seeking to end the shares’ registration and suspend its reporting obligations.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 1.02 Termination of a Material Definitive Agreement Business
A significant contract was terminated, which may affect business operations or revenue.
Item 2.01 Completion of Acquisition or Disposition of Assets Financial
The company completed a significant acquisition or sale of business assets.
Item 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation Financial
An event triggered acceleration or increase of an existing financial obligation, such as a debt covenant breach.
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Item 3.03 Material Modification to Rights of Security Holders Securities
A change was made that materially affects the rights of existing shareholders (e.g., dividend rights, voting rights).
Item 5.01 Changes in Control of Registrant Governance
A change in control of the company occurred, such as through a merger, takeover, or management buyout.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Merger consideration $36.50 per share Cash payable for each eligible outstanding share in the merger, subject to applicable withholding taxes and without interest.
Shares validly tendered 32,929,780 shares Validly tendered and not properly withdrawn; excludes guaranteed-delivery shares not yet received by the depositary.
Tendered shares plus Purchaser and affiliate holdings Approximately 66.46% Of Pacira’s issued and outstanding shares as of the offer’s expiration.
Funds required for share payments and certain debt repayment Approximately $1.69 billion Excludes transaction fees and expenses and Pacira cash and cash equivalents assumed by Viatris.
Credit agreement balance repaid $96,392.50 Outstanding amount repaid in full on November 17, 2026, when the agreement and commitments were terminated.
Convertible notes outstanding $287.5 million 2.125% Convertible Senior Notes due 2029, outstanding as of November 17, 2026.
Make-whole conversion amount $1,103.8914 per $1,000 principal For valid conversions through 5:00 p.m. New York City time on January 8, 2027.
Conversion amount after make-whole period $922.5448 per $1,000 principal For other times when the notes are convertible after the make-whole period.
Make-Whole Fundamental Change financial
"the Make-Whole Fundamental Change conversion period"
A make-whole fundamental change is a contract clause that requires a company to compensate holders of certain securities (often convertible bonds or preferred shares) if a big event—like a merger, acquisition, or restructuring—removes or reduces the holders’ expected future benefits. Think of it as a shortcut payment that aims to leave investors financially ‘whole’ for lost upside or income, and it matters because it affects how much those investors get paid and how much such an event will cost the company.
Reference Property financial
"the kind and amount of shares of stock, other securities or other property"
Conversion Rate financial
"the Conversion Rate in effect on the applicable Conversion Date"
Conversion rate is the proportion of items, people or contracts that take a desired action out of the total possible — for example the share of website visitors who make a purchase, or the number of convertible bonds that are exchanged for shares. Investors care because it measures how effectively a business or financial instrument turns opportunity into real outcomes, like sales or share issuance, which directly affects revenue, cash flow and ownership dilution.
Additional Shares financial
"4.9684 Additional Shares per $1,000 principal amount of Notes"
statutory rights of appraisal regulatory
"properly exercised and perfected their statutory rights of appraisal"
Business Day financial
"the tenth (10th) Business Day immediately following the relevant Conversion Date"
A business day is any weekday when banks, stock exchanges and most government offices are open for normal operations, excluding weekends and public holidays. For investors it matters because transaction timing, settlement of trades, filing deadlines and interest calculations are all measured in business days—think of it as the financial world’s working calendar that determines when money moves and official actions take effect.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PCRX shareholders receive in the Viatris merger?

Each eligible Pacira share outstanding at the merger’s effective time converted into the right to receive $36.50 in cash, subject to applicable withholding taxes and without interest. Shares held by Pacira, its subsidiaries, Viatris or its subsidiaries, and shares covered by perfected appraisal rights were excluded.

How many Pacira shares were tendered in Viatris’ offer?

Viatris reported 32,929,780 shares validly tendered and not properly withdrawn before the offer expired. Together with shares then owned by Purchaser and its affiliates, the shares represented approximately 66.46% of Pacira’s issued and outstanding shares; the count excludes guaranteed-delivery shares not yet received by the depositary.

How much cash can holders receive for converting PCRX’s 2.125% notes due 2029?

For notes validly surrendered from November 17, 2026 through 5:00 p.m. New York City time on January 8, 2027, the cash conversion amount is $1,103.8914 per $1,000 principal. After that period, the amount is $922.5448 per $1,000 principal when notes are otherwise convertible. Notes convert only into cash, payable on the tenth Business Day after conversion.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 17, 2026

Pacira BioSciences, Inc.
(Exact name of registrant as specified in its charter)

Delaware
001-35060
51-0619477
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

2000 Sierra Point Parkway, Suite 900
Brisbane, California 94005
(Address and Zip Code of Principal Executive Offices)

(650) 242-8052
(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trading symbol
 
Name of each exchange on which registered
Common Stock, par value $0.001 per share
 
PCRX
 
Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Introductory Note
 
As previously disclosed, on October 8, 2026, Pacira BioSciences, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Viatris Inc., a Delaware corporation (“Viatris”), and Peach Purchaser Sub Inc., a Delaware corporation and wholly owned subsidiary of Viatris (“Purchaser”).
 
Item 1.01
Entry into a Material Definitive Agreement.
 
Supplemental Indenture
 
In connection with the consummation of the Merger (as defined below), the Company and Computershare Trust Company, National Association (the “Trustee”), entered into a First Supplemental Indenture (the “Supplemental Indenture”), dated as of November 17, 2026, which amends and supplements the Indenture (the “Original Indenture” and, together with the Supplemental Indenture, the “Indenture”), dated as of May 14, 2024, by and between the Company and the Trustee, governing the Company’s 2.125% Convertible Senior Notes due 2029 (the “Notes”), of which $287.5 million in aggregate principal amount is outstanding as of the date hereof.
 
The Supplemental Indenture provides that, among other things, from and after the Effective Time (as defined below), the right to convert each $1,000 principal amount of Notes into Shares (as defined below) has been changed into a right to convert such principal amount of Notes solely into Reference Property (as defined in the Indenture) consisting of cash equal to $36.50 multiplied by the Conversion Rate in effect on the relevant Conversion Date (including, for conversions in connection with the Make-Whole Fundamental Change, any Additional Shares (each as defined in the Indenture)), payable on the tenth Business Day following such Conversion Date. The Merger, pursuant to which the Shares were converted solely into the right to receive cash, constitutes a Common Stock Change Event, a Make-Whole Fundamental Change, a Fundamental Change and an Exempted Fundamental Change (each as defined in the Indenture) with respect to the Notes. In connection with the Merger, the Company elected to rely on Section 14.05 of the Indenture and will not offer to repurchase any Notes in connection with the Merger.
 
Unwind Agreements in respect of the Capped Call Transactions
 
As previously disclosed, in connection with the issuance of the Notes, the Company entered into capped call transactions (the “Capped Call Transactions”) with certain financial institution counterparties (the “Capped Call Counterparties”), as evidenced by the confirmations, additional confirmations and related side letters and additional side letters (together, the “Capped Call Confirmations”). On November 17, 2026, the Company entered into an unwind agreement for each Capped Call Confirmation with each Capped Call Counterparty in exchange for an agreed upon cash payment by such Capped Call Counterparty to the Company, payable on or about November 17, 2026.
 
The foregoing description of the Indenture and the Capped Call Transactions does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Original Indenture, which was filed as Exhibit 4.1 of the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 14, 2024 (the “May 14, 2024 Form 8-K”), and is incorporated into this Item 1.01 by reference, the full text of a form of the Capped Call Confirmation, which was filed as Exhibit 10.1 of the May 14, 2024 Form 8-K, and is incorporated into this Item 1.01 by reference, and the full text of the Supplemental Indenture, which is filed as Exhibit 4.1 hereto and incorporated into this Item 1.01 by reference.
 
Item 1.02
Termination of Material Definitive Agreement.
 
In connection with the consummation of the Merger, on November 17, 2026, $96,392.50, which represented all amounts outstanding under the Credit Agreement, dated as of July 3, 2025, by and among the Company, the lenders from time to time party thereto and Wells Fargo Bank, National Association, as administrative agent, swingline lender and an issuing bank (as amended, restated, or otherwise modified from time to time, the “Credit Agreement”), was repaid in full, the Credit Agreement and all commitments thereunder were terminated and all liens securing obligations under the Credit Agreement will be released.
 
The foregoing description of the Credit Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Credit Agreement, which was filed as Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on July 7, 2025, and is incorporated into this Item 1.02 by reference.
 

Item 2.01
Completion of Acquisition or Disposition of Assets.
 
As previously disclosed, pursuant to the Merger Agreement, on October 30, 2026, Purchaser commenced a tender offer to acquire all of the outstanding shares of common stock of the Company, $0.001 par value per share (the “Shares”), at an offer price of $36.50 per Share in cash, net of applicable withholding taxes and without interest (the “Offer Price”), upon the terms and subject to the conditions set forth in the Offer to Purchase, dated October 30, 2026 (as amended or supplemented from time to time, the “Offer to Purchase”), and in the related Letter of Transmittal (which, together with the Offer to Purchase and other related materials, as amended or supplemented from time to time, constituted the “Offer”).
 
On November 17, 2026, Viatris announced that the Offer and related withdrawal rights had expired as scheduled at one minute following 11:59 p.m., Eastern Time, on November 16, 2026 (the “Expiration Date”) and the Offer was not extended, and that as of such time, based on the information provided by the depositary and paying agent for the Offer, a total of 32,929,780 Shares, together with the Shares then owned by Purchaser and its “affiliates” (as such term is defined in Section 251(h)(6)(a) of the General Corporation Law of the State of Delaware (the “DGCL”)), were validly tendered (and not properly withdrawn) pursuant to the Offer prior to the Expiration Date (excluding Shares tendered pursuant to guaranteed delivery procedures that have not yet been “received,” as such term is defined in Section 251(h)(6)(f) of the DGCL, by the “depository,” as such term is defined in Section 251(h)(6)(c) of the DGCL), representing approximately 66.46% of the issued and outstanding Shares as of the Expiration Date.
 
Accordingly, the number of Shares validly tendered (and not properly withdrawn) and received by the depositary pursuant to the Offer, together with the Shares then owned by Purchaser and its affiliates, satisfied the Minimum Condition (as defined in the Merger Agreement), and all other conditions to the consummation of the Offer had been satisfied or waived. As a result of the satisfaction of the Minimum Condition and each of the other conditions to the Offer, on November 17, 2026, Purchaser irrevocably accepted for payment all Shares that were validly tendered (and not properly withdrawn) pursuant to the Offer.
 
Following the consummation of the Offer, the remaining conditions to the Merger set forth in the Merger Agreement were satisfied or waived, and the parties to the Merger Agreement consummated the Merger on November 17, 2026. Pursuant to the Merger Agreement, at the date and time of the filing of the certificate of merger with the Secretary of State of the State of Delaware (the “Effective Time”), Purchaser was merged with and into the Company (the “Merger”), without a vote on the adoption of the Merger Agreement by the Company’s stockholders, in accordance with Section 251(h) of the DGCL, with the Company continuing as the surviving corporation of the Merger (the “Surviving Corporation”) and as a wholly owned subsidiary of Viatris. At the Effective Time and as a result of the Merger, each Share issued and outstanding immediately prior to the Effective Time (other than Shares held (i) by the Company or its subsidiaries (including Shares held in the Company’s treasury), (ii) by Viatris, Purchaser, or any other direct or indirect wholly owned subsidiary of Viatris, or (iii) by stockholders of the Company who have properly exercised and perfected their statutory rights of appraisal under the DGCL) was automatically converted into the right to receive the Offer Price.
 
Pursuant to the terms of the Merger Agreement, each option to purchase Shares (each, a “Company Option”) that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per Share under such Company Option, subject to applicable tax withholdings; provided, that any Company Option that had an exercise price per Share that was greater than or equal to the Offer Price was canceled at the Effective Time without any consideration payable (whether in the form of cash or otherwise) therefor, whether before or after the Effective Time.
 
Pursuant to the terms of the Merger Agreement, each performance share unit award (each, a “Company PSU”) that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares issuable in settlement of such Company PSU, which was based on deemed achievement of the applicable performance metrics at 100% of target, as determined in accordance with the applicable Company PSU award agreement, multiplied by (ii) the Offer Price, subject to applicable tax withholdings.
 
Pursuant to the terms of the Merger Agreement, each restricted stock unit award (each, a “Company RSU”) that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares issuable in settlement of such Company RSU, multiplied by (ii) the Offer Price, subject to applicable tax withholdings.
 

Pursuant to the terms of the Merger Agreement, each cash-based award granted pursuant to the Company’s cash-based long-term incentive plan (each, a “Company LTIP Award”) that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled at the Effective Time and converted into the right to receive cash in an amount determined by the Company’s board of directors (the “Board”), pursuant to the terms of the plan, based on actual achievement of the applicable performance metrics (as previously disclosed for awards granted in 2024 and 2025 and at 107.8% of target as of the closing of the Merger for awards granted in 2026), subject to applicable tax withholdings.
 
Pursuant to the terms of the Merger Agreement, each restricted cash award (a “Company Restricted Cash Award”) that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled at the Effective Time and converted into the right to receive an amount of cash equal to the sum of (i) any portion of the Company Restricted Cash Award that was vested, but remained unpaid, as of the Effective Time and (ii) the amount of Unvested Cash (as defined under the applicable Company Restricted Cash Award agreement) with respect to the Company Restricted Cash Award.
 
The total amount of funds required to pay for the Shares in the Offer and the Merger and to repay certain indebtedness of the Company, was approximately $1.69 billion. These amounts exclude (i) fees and expenses related to the Offer and the Merger and (ii) any Company cash and cash equivalents assumed by Viatris. Viatris provided Purchaser with sufficient funds to purchase all Shares accepted for payment pursuant to the Offer and all Shares purchased in the Merger using Viatris’ available cash on hand and short-term borrowings.
 
The foregoing description of the Merger Agreement and the related transactions does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement, a copy of which was filed as Exhibit 2.1 to the Current Report on Form 8-K filed by the Company with the SEC on October 8, 2026, and is incorporated herein by reference.
 
The disclosure contained under the Introductory Note above is incorporated herein by reference.
 
Item 2.04.
Triggering Events that Accelerate or Increase a Direct Financial Obligations or an Obligation under an Off-Balance Sheet Arrangement.
 
The disclosure contained under the Introductory Note and in Items 1.01, 1.02 and 2.01 above is incorporated herein by reference.
 
Item 3.01.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
 
On November 17, 2026, the Company notified The Nasdaq Global Select Market (“Nasdaq”) of the consummation of the Merger, and requested that Nasdaq (i) halt trading of the Shares prior to market open on November 17, 2026 and (ii) file with the SEC a Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on Form 25 to effect the delisting of the Shares from Nasdaq and to deregister the Shares under Section 12(b) of the Exchange Act. In addition, the Company intends to file with the SEC a certification on Form 15 under the Exchange Act requesting the termination of registration of the Shares under Section 12(g) of the Exchange Act and the suspension of the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act.
 
The disclosure contained under the Introductory Note and in Item 2.01 above is incorporated herein by reference.
 
Item 3.03.
Material Modification to Rights of Security Holders.
 
The disclosure contained under the Introductory Note and in Items 1.01, 2.01 and 3.01 above and in Items 5.01 and 5.03 below is incorporated herein by reference.
 
Item 5.01.
Changes in Control of Registrant.
 
The disclosure contained under the Introductory Note and in Item 2.01 above and in Items 5.02 and 5.03 below is incorporated herein by reference.
 
As a result of the consummation of the Offer and the Merger pursuant to Section 251(h) of the DGCL, on November 17, 2026, a change in control of the Company occurred. At the Effective Time, the Company became a wholly owned subsidiary of Viatris.
 

Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
In connection with the Merger and pursuant to the Merger Agreement, at the Effective Time, each of Frank D. Lee, Marcelo Bigal, Laura Brege, Christopher Christie, Mark Froimson, Samit Hirawat, Thomas Wiggans, Michael Yang and Alethia Young ceased serving as a member of the Board and each committee thereof, and each of Frank D. Lee, Shawn Cross, Kristen Williams, Brendan Teehan, Jonathan Slonin and Lauren Riker ceased serving as an officer of the Company.
 
Further, in connection with the Merger and pursuant to the Merger Agreement, at the Effective Time, John Miraglia and Michael Rainerman became the officers and directors of the Surviving Corporation. Information regarding the new officers and directors of the Surviving Corporation had been previously disclosed in the Tender Offer Statement on Schedule TO, filed by Viatris and Purchaser with the SEC on October 30, 2026 (together with the exhibits and annexes thereto and as amended or supplemented from time to time).
 
Item 5.03.
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
 
In connection with the Merger and pursuant to the Merger Agreement, at the Effective Time, the second amended and restated certificate of incorporation of the Company and the third amended and restated bylaws of the Company were each amended and restated in their entirety. Copies of the third amended and restated certificate of incorporation of the Company (the “Third A&R Certificate of Incorporation”) and fourth amended and restated bylaws of the Company (the “Fourth A&R Bylaws”) are filed as Exhibits 3.1 and 3.2 hereto, respectively.
 
The foregoing description of the Third A&R Certificate of Incorporation and the Fourth A&R Bylaws does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Third A&R Certificate of Incorporation and the Fourth A&R Bylaws, which are incorporated into this Item 5.03 by reference.
 
Item 7.01
Regulation FD Disclosure
 
On November 17, 2026, the Company delivered notice to the holders of the Notes (the “Notice”) announcing that the closing of the Merger constitutes a Common Stock Change Event, a Make-Whole Fundamental Change, a Fundamental Change and an Exempted Fundamental Change. A copy of the Notice is filed as Exhibit 99.1.
 
The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to liabilities under that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings.
 
Item 9.01
Financial Statements and Exhibits.
 
(d)
Exhibits
 
Exhibit No.
Description
2.1*
Agreement and Plan of Merger, dated as of October 8, 2026, by and among Pacira BioSciences, Inc., Viatris Inc. and Peach Purchaser Sub Inc. (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on October 8, 2026).
   
3.1
Third Amended and Restated Certificate of Incorporation of Pacira BioSciences, Inc.
   
3.2
Fourth Amended and Restated Bylaws of Pacira BioSciences, Inc.
   
4.1
First Supplemental Indenture, dated as of November 17, 2026, by and between Pacira BioSciences, Inc. and Computershare Trust Company, National Association, as trustee.
   
99.1
Notice to Holders of Pacira BioSciences, Inc. 2.125% Convertible Senior Notes Due 2029 of Supplemental Indenture, Common Stock Change Event, Make-Whole Fundamental Change, Exempted Fundamental Change and Conversion Rights.
   
104
Cover Page Interactive Data File (Formatted as Inline XBRL).
   
*
Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally to the SEC a copy of any omitted exhibits or schedules upon request.


SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
PACIRA BIOSCIENCES, INC.
(REGISTRANT)
     
Date: November 17, 2026
By:
/s/ Michael Rainerman
   
Name: Michael Rainerman
   
Title: President

 


Exhibit 99.1
 
November 17, 2026

To:      Holders of Pacira BioSciences, Inc.
2.125% Convertible Senior Notes due 2029 (CUSIP: 695127AJ9)

and

Computershare Trust Company, National Association
as Trustee, Paying Agent and Conversion Agent
Corporate Trust Office
1505 Energy Park Drive
St. Paul, MN 55108
Attn: Corporate Trust Services – Pacira BioSciences, Inc. Administrator

RE:
NOTICE TO HOLDERS OF PACIRA BIOSCIENCES, INC. 2.125% CONVERTIBLE SENIOR NOTES DUE 2029 OF SUPPLEMENTAL INDENTURE, COMMON STOCK CHANGE EVENT, MAKE-WHOLE FUNDAMENTAL CHANGE, EXEMPTED FUNDAMENTAL CHANGE AND CONVERSION RIGHTS

Pacira BioSciences, Inc., a Delaware corporation (the “Company”) and Computershare Trust Company, National Association, a national banking association and limited purpose trust company organized under the laws of the United States, as trustee (the “Trustee”), as paying agent (the "Paying Agent") and as conversion agent (the "Conversion Agent") executed that certain Indenture, dated as of May 14, 2024 (as so supplemented, the “Indenture”), concerning the 2.125% Convertible Senior Notes due 2029 (CUSIP: 695127AJ9) (the “Notes”). Capitalized terms used but not otherwise defined in this Notice have the meanings given to them in the Indenture. A copy of the Indenture was filed as Exhibit 4.1 to Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on May 14, 2024. The Trustee also serves as Paying Agent and Conversion Agent under the Indenture.

This Notice is being delivered to the Holders, the Trustee and the Conversion Agent for the Notes in accordance with Sections 13.01(b)(iii), 13.03, 13.07 and 14.05 of the Indenture in connection with the Merger (as defined below), the execution of the First Supplemental Indenture (as defined below), the resulting Common Stock Change Event, Make-Whole Fundamental Change and Fundamental Change, and the Company's reliance on Section 14.05 of the Indenture. This Notice does not constitute a Fundamental Change Company Notice under Section 14.01(c) of the Indenture, and the Company is not offering to repurchase, and will not repurchase, any Notes pursuant to Article 14 of the Indenture in connection with the Merger.
 
On October 8, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, Viatris Inc., a Delaware corporation (“Parent”), and Peach Purchaser Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Purchaser”). Pursuant and subject to the Merger Agreement, Parent and Purchaser commenced a tender offer (the “Offer”) on October 30, 2026 to acquire all of the outstanding shares of Common Stock, at a purchase price of $36.50 in cash, without interest and subject to applicable withholding taxes (the “Offer Price”). The Offer was consummated on November 17, 2026 (the "Effective Date"), and following the consummation of the Offer, Purchaser was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the “Merger”, and together with the Offer, the “Transaction”). At the effective time of the Merger (the "Effective Time"), each share of Common Stock then outstanding (other than the excluded shares and dissenting shares as described in the Merger Agreement) was converted into the right to receive the Offer Price (the “Merger Consideration”).
 
The consummation of the Transaction constitutes a Common Stock Change Event, a Make-Whole Fundamental Change, a Fundamental Change and an Exempted Fundamental Change under the Indenture, each as of the Effective Date. As described below, the Indenture also provides that, as a result of the Common Stock Change Event, the Company and the Trustee were required to execute a supplemental indenture to change each Holder’s right to convert each $1,000 principal amount of Notes into the right to convert each $1,000 principal amount of Notes into the kind and amount of shares of stock, other securities or other property or assets (which in the case of the Merger will be cash, based on the Merger Consideration) that a Holder of a number of shares of Common Stock equal to the Conversion Rate immediately prior to the Effective Time of the Merger would have owned or been entitled to receive upon the Effective Time of the Merger (the “Reference Property”). The Company and the Trustee did enter into such a supplemental indenture (the "First Supplemental Indenture"), a copy of which is attached to this Notice as Exhibit A.

You should review this Notice carefully and consult with your financial and tax advisors. You must make your own decision as to whether or not to exercise your conversion rights (if at all) and, if so, the timing of the conversion and the amount of Notes to surrender or convert. None of the Company, Parent, Purchaser, Trustee, Paying Agent, Conversion Agent or any of their respective affiliates are making any representation or recommendation to any Holder as to whether Holders should elect to convert their Notes or take or decline taking any other action.
 

The First Supplemental Indenture
 
Pursuant to the First Supplemental Indenture, from and after the Effective Time, the right to convert each $1,000 principal amount of Notes into shares of Common Stock has been changed into a right to convert such principal amount of Notes solely into cash in an amount equal to $36.50 (which, for all purposes, shall be considered the last reported sale price) multiplied by the Conversion Rate in effect on the applicable Conversion Date, which for a limited period of time, will include an increase reflecting Additional Shares pursuant to Section 13.03 of the Indenture. For the avoidance of doubt, from and after the Effective Time, Holders do not have the right to convert Notes into shares of Common Stock or other securities of the Company.
 
The Company is relying on Section 14.05 of the Indenture in connection with the Merger. Accordingly, the Company is not required to send a Fundamental Change Notice pursuant to Section 14.01, or offer to repurchase or repurchase any Notes pursuant to Article 14.
 
As a result of the Make-Whole Fundamental Change, each Holder of the Notes will have the right to surrender the Holder’s Notes for conversion. Additional Shares will be added to the Conversion Rate for Notes surrendered in connection with the Make-Whole Fundamental Change, pursuant to Section 13.03 of the Indenture.
 
Conversion Rights, Conversion Rate and Make-Whole Adjustment
 
The effective date of the Make-Whole Fundamental Change resulting from the consummation of the Offer and the Merger is the Effective Date. As a result of the Make-Whole Fundamental Change, a Holder may surrender its Notes for conversion at any time from or after the Effective Date, which is November 17, 2026, until 35 Trading Days after the Effective Date, which is January 8, 2027, pursuant to Section 13.01(b)(iii) of the Indenture. In accordance with Sections 2.01 of the First Supplemental Indenture and 13.02 of the Indenture, Holders who surrender their Notes for conversion from and after the Effective Time at any time when the Notes are convertible will receive cash in an amount equal to the Conversion Rate in effect immediately prior to the Effective Date of the Merger, multiplied by the Merger Consideration per share of $36.50, and will not receive any shares of the Common Stock.
 
Because the consummation of the Transaction constitutes a Make-Whole Fundamental Change, in accordance with Section 13.03 of the Indenture, the Conversion Rate for Notes surrendered for conversion any time beginning on November 17, 2026, the Effective Date of the Make-Whole Fundamental Change, until 5:00 p.m. (New York City time) on January 8, 2027, which is the thirty-fifth (35th) Trading Day immediately following the Effective Date), will be increased to the Make-Whole Conversion Rate as described below. During that period, Holders that validly surrender Notes for conversion in accordance with the Indenture will be entitled to receive $1,103.8914 in cash per $1,000 principal amount of Notes converted, based on the base Conversion Rate of 25.2752 shares of Common Stock per $1,000 principal amount of Notes plus 4.9684 Additional Shares per $1,000 principal amount of Notes.
 
Following the Make-Whole Fundamental Change conversion period described above, Holders that validly surrender Notes for conversion at any other time when the Notes are convertible under the Indenture will be entitled to receive $922.5448 in cash per $1,000 principal amount of Notes converted, based on the base Conversion Rate of 25.2752 shares of Common Stock per $1,000 principal amount of Notes. In either case, the Company will satisfy the Conversion Obligation by paying cash to converting Holders on the tenth (10th) Business Day immediately following the relevant Conversion Date. The Conversion Rate after such period does not reflect any Additional Shares and, consequently, any Holder that surrenders their Notes for conversion after the Make-Whole Fundamental Change conversion period will receive less than they would have had they instead validly surrendered their Notes for conversion prior to the end of such period.
 
2

Conversion Procedures
 
A Holder may convert a portion of a Note, but only if that portion is an integral multiple of $1,000 in principal amount. The Trustee has informed the Company that, as of the date of this Notice, the Depositary is the sole registered Holder of the Notes, all custodians and beneficial holders of the Notes hold the Notes through DTC accounts and there are no certificated Notes in non-global form. To convert a beneficial interest in a Note that is a Global Note, the beneficial owner must comply with the applicable procedures of the Depositary to cause to be delivered to the Conversion Agent through the facilities of the Depositary in accordance with the applicable procedures of the Depositary, the interest in the Global Note to be converted, accompanied by payment of any documentary, stamp or similar issue or transfer taxes, in accordance with Sections 13.02 of the Indenture. A Form of Notice of Conversion is included with the Indenture as Attachment 1.
 
The Trustee is acting as the Conversion Agent, and its address is as follows:
 
Computershare Trust Company, National Association
Corporate Trust Services
1505 Energy Park Drive
St. Paul, MN 55108
Email: #NACCTCPUCONVERSIONS@COMPUTERSHARE.COM
 
Backup Withholding
 
To avoid the application of a 24% backup withholding tax on any payments made to certain converting Holders (or other payees), each converting Holder (or other payee) should complete and provide an Internal Revenue Service (“IRS”) Form W-9 (in the case of a Holder that is a U.S. person or resident alien for U.S. federal income tax purposes) or an IRS Form W-8BEN or other appropriate IRS Form W-8 (in the case of a Holder that is a non-U.S. person for U.S. federal income tax purposes).
 
General
 
None of the Company, Parent, Purchaser, the Trustee, the Paying Agent, the Conversion Agent or any of their respective affiliates or any other person will be under any duty to give notification of any defects or irregularities in tenders or conversions, or withdrawal of tenders, or incur any liability for failure to give any such notification.
 
Pacira BioSciences, Inc.
 
3

Exhibit A
 
FIRST SUPPLEMENTAL INDENTURE
 


Filing Exhibits & Attachments

7 documents

Keep reading